FIRST ANALYSIS NEWS
First Analysis Acted as Exclusive Placement Agent in Apixio’s $13.5 Million
Series C Financing Led by Bain Capital Ventures
Apixio

CHICAGO – May 14, 2014 – First Analysis acted as the exclusive placement agent in a $13.5 million growth capital raise, closed in April 2014, for Apixio Inc. - a leading provider of big data solutions for healthcare analytics. First Analysis provided advisory expertise to Apixio throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.

The equity investment was led by Bain Capital Ventures, who has extensive investment and operating experience in Healthcare Technology. This capital infusion will enable Apixio to scale its sales and operations, further strengthen its proprietary technology and IP, and accelerate the commercialization of additional service offerings.

“First Analysis was instrumental to the successful outcome of this transaction. Their industry expertise and strong venture capital relationships helped push our conversations with investors forward, giving us negotiating leverage and delivering very competitive term sheets from top tier firms,” said Shawn Dastmalchi, CEO of Apixio. “We are very excited about working with Bain Capital Ventures in the next phase of our growth plan.”

About Apixio

Headquartered in San Mateo, CA, Apixio’s big data analytics solution extracts unstructured data from the health system, applies natural language processing and machine learning technology to provide automated actionable insights based on clinical information that enable payors and providers to maximize revenue from risk-based outcome payment models. By using the Company’s HCC Optimizer software to accurately code the disease burden of its members, Medicare Advantage plans can ensure that they receive appropriate reimbursement while minimizing audit risk.


For more information about this transaction, or with questions about how we can assist you or your clients, please contact the following First Analysis representatives:

Matt Nicklin
Managing Director
mnicklin@firstanalysis.com
312-258-7181

Brian Friedman
Managing Director
bfriedman@firstanalysis.com
312-258-7110

Josh Moses
Vice President
jmoses@firstanalysis.com
312-258-7180

About First Analysis

Founded in 1981, First Analysis has over a 30-year track record of serving emerging growth companies and established industry leaders within its focused areas of domain expertise. Our investment banking practice leverages industry insights developed through our equity research and private equity activities to deliver value to clients across the life cycle of a business.

Providing senior-level attention to every client, First Analysis offers superior execution across a comprehensive range of investment banking services, including M&A advisory, public equity and debt financing, and private equity placements.

For additional information about how the investment banking professionals at First Analysis Securities Corporation can help you, please visit our website, www.firstanalysis.com, or call us at (312) 258-1400.


To download a pdf version of this press release, please follow the link below:
First Analysis Represents Apixio in Series C Financing Led by Bain Capital Ventures

First Analysis Securities Corp. (FASC) is a registered broker/dealer with FINRA and member SIPC.

Investment banking and corporate finance services are offered through First Analysis Securities Corporation ("FASC" or "First Analysis Securities"), a subsidiary of First Analysis Corp.
©2020 by First Analysis Corporation.
One South Wacker Drive
  ·  
Suite 3900
  ·  
Chicago, IL 60606
  ·  
312-258-1400
First Analysis Securities Corp. (FASC) is a registered broker/dealer with FINRA and member SIPC.